CTLA4 and melanoma: Hence, peripheral blood, which can be repeatedly obtained during therapy in a minimally invasive manner, is an attractive alternative, despite not representing the place “where the action is.” Here we summarize predominantly our own work on constellations of peripheral biomarkers informative for responses to ICI (mostly anti-CTLA-4 or anti-PD-1 in melanoma).